7x24英文

00:05 Merck bails on Lantus biosimilar - Biocon Ltd. ADR (OTCMKTS:BCNQY)

英文24小时播报 4天前 1469

FiercePharma reports that Merck (MRK +1.4%) has decided to exit the Lantus biosimilar market after failing to make sufficient headway since the FDA's tentative nod in July 2017.

The company has canceled its development and commercialization agreement with Samsung Bioepis for the product, branded as Lusduna Nexvue, but will continue with biosimilar programs in oncology and immunology.

Merck's withdrawal leaves Mylan/Biocon and Eli Lilly/Boehringer Ingelheim as the only biosimilar competitors to Sanofi's Lantus.

(MYL -1.4%) (OTC:BCNQY) (LLY +2.1%)(SNY -2.5%)

$BCNQY

Subscribe for full text news in your inbox

更多资讯 ->
发新帖
英文24小时播报
主题数
-2
帖子数
0
注册排名
5